The Next Steps: Opioid Use Disorder Care After the ED

Dr. Andrew Herring
Dr. Evan Schwarz
Dr. Scott Weiner
Dr. Lewis Nelson

STR-TA Consortium
State Targeted Response Technical Assistance
Working with communities to address the opioid crisis.

✧ SAMHSA’s State Targeted Response Technical Assistance (STR-TA) Consortium assists STR grantees and other organizations, by providing the resources and technical assistance needed to address the opioid crisis.

✧ Technical assistance is available to support the evidence-based prevention, treatment, and recovery of opioid use disorders.

Funding for this initiative was made possible (in part) by grant no. 1H79TI080816-01 from SAMHSA. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.
Working with communities to address the opioid crisis.

- The STR-TA Consortium provides local expertise to communities and organizations to help address the opioid public health crisis.
- The STR-TA Consortium accepts requests for education and training resources.
- Each state/territory has a designated team, led by a regional Technology Transfer Specialist (TTS) who is an expert in implementing evidence-based practices.

Funding for this initiative was made possible (in part) by grant no. 1H79TI080816-01 from SAMHSA. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.
Contact the STR-TA Consortium

✧ To ask questions or submit a technical assistance request:

- Visit www.getSTR-TA.org
- Email str-ta@aaap.org
- Call 401-270-5900

Funding for this initiative was made possible (in part) by grant no. 1H79TI080816-01 from SAMHSA. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.
Saving Lives: Bringing Buprenorphine to Emergency Care

Andrew A Herring, MD
Associate Research Director, Department of Emergency Medicine
Medical Director Substance Use Disorder Program PI,
California Bridge Project
Highland Hospital—Alameda Health System
Assistant Clinical Professor of Emergency Medicine, UCSF
How can emergency services contribute to systems of care for people who use opioid drugs?

✧ The answer varies depending on:

– The individual and unique needs of your community at any point in time during this rapidly evolving epidemic.

– The capacity of healthcare and use disorder system outside of emergency department and hospital.
Need help with Pain Pills or Heroin?
We want to help you get off opioids and started on Suboxone (Buprenorphine.)
Ask here for more information.
Emergency Access to Buprenorphine

Many sites of care for opioid use disorder lack capacity to:

1) Start buprenorphine on demand 24-7.
2) Arrange timely follow up after Buprenorphine has been started.

The ED fills these gaps.

• no patient who wants treatment is abandoned
Bridge Program Staffed By EM Attendings and Residents

**Bridge Clinic**
Care navigator M-F; 9-5
Weekly drop in Bridge clinic

Emergency Department attendings, residents and medical students staff Bridge Clinic

One day in bridge clinic = one day shift
All visits billed as outpatient visits
Case Example

1. **Specialty Care: Orthopedics**
   - Medical Opioid Exposure
   - Use disorder develops
   - Opioid discontinuation
   - Heroin & Fentanyl

2. **Residential Substance Use Disorder Treatment**
   - Street Medicine Team
   - Needle Exchange Sites

3. **Emergency Department**
   - Always crowded
   - Front desk
   - Fast Track Area

4. **On-site, Substance Use Disorder Treatment Program**

5. **Bridge Program**

6. **Residential Substance Use Disorder Treatment**
   - Primary Care

7. **Engagement -- Disengagement**

     (1 week to 6 months)
Increased Utilization

Monthly Totals

21 Months (1/2017-9/2018)
Changed Culture

574
Unique patients treated with buprenorphine

436
Made contact with navigator

297
Accepted referral

249
Arrived at follow up
A Community Approach

Evan Schwarz FACEP, FACMT
Associate Professor of Emergency Medicine
Washington University School of Medicine
Barnes Jewish Hospital
Saint Louis, MO
Our Process

ED: Calls Central Agency

Recovery Coach

Behavioral Health Network of Greater St. Louis

5 Treatment Centers in St. Louis Receiving State Funds
Recovery Coach In the ED

Meets with patient. Gets additional ‘buy-in’

Sets up follow up and arranges them getting there

Normally in 0-3 days

Gives them naloxone

Each patient receives a phone number to call

Fills buprenorphine prescription

Between 20-30 waived ED physicians

PATIENTS HAVE BEEN VERY RECEPTIVE TO THIS
If you have good insurance or financial resources?

ED Calls → Treatment Center Follow up Obtained → Bup in the ED/ Naloxone prescription

Treatment Programs Contacted Us Once They Saw That We Had This Interest They Actually Want Our Referrals and Are Willing to Work With Us
In Summary...

- Little burden on EM physician on shift
- Took time/effort to set up beforehand
  - Traditionally, no assistance from community
  - Now the centers are very engaged (\textit{& costs us nothing})
- Poorer patients receive meds, naloxone for free and wrap around services
- Those with resources are also directly connected
- Physicians, nursing, staff, social workers are all very supportive and process flows smoothly
Addiction Treatment at Brigham Health

Scott G. Weiner, MD, MPH
Associate Professor, Harvard Medical School
Director, Brigham Comprehensive Opioid Response and Education (B-CORE Program)
Chief, Division of EM Health Policy and Public Health
Department of Emergency Medicine
Brigham and Women’s Hospital, Boston, MA

Thanks to Christin Price, MD
PHM Perspective: Becoming a Medicaid ACO

<table>
<thead>
<tr>
<th>Top 5% Highest Cost Members</th>
<th>Next 10% Highest Cost Members</th>
<th>85% Lowest Cost Members</th>
</tr>
</thead>
<tbody>
<tr>
<td>Condition</td>
<td>Condition</td>
<td>Condition</td>
</tr>
<tr>
<td>Drug/Alcohol Abuse, (both Dependence and w/o Dependence)</td>
<td>Drug/Alcohol Abuse, (both Dependence and w/o Dependence)</td>
<td>Drug/Alcohol Abuse, (both Dependence and w/o Dependence)</td>
</tr>
<tr>
<td>Major Depressive, Bipolar, Paranoid</td>
<td>Major Depressive, Bipolar, Paranoid</td>
<td>Major Depressive, Bipolar, Paranoid</td>
</tr>
<tr>
<td>Hypertension</td>
<td>Hypertension</td>
<td>Hypertension</td>
</tr>
<tr>
<td>Diabetes (w/ Complications and w/c Complications)</td>
<td>Asthma</td>
<td>Diabetes (w/ Complications and w/c Complications)</td>
</tr>
<tr>
<td>Asthma</td>
<td>Depression</td>
<td>Depression</td>
</tr>
<tr>
<td>Depression</td>
<td>Chronic Obstructive Pulmonary Disease</td>
<td>Attention Deficit Disorder</td>
</tr>
<tr>
<td>Chronic Obstructive Pulmonary Disease</td>
<td>Disorders of Vertebrae/Spinal Discs</td>
<td>Diabetes (w/ Complications and w/c Complications)</td>
</tr>
<tr>
<td>Disorders of Vertebrae/Spinal Discs</td>
<td>Attention Deficit Disorder</td>
<td>Disorders of Vertebrae/Spinal Discs</td>
</tr>
<tr>
<td>Attention Deficit Disorder</td>
<td>Chronic Obstructive Pulmonary Disease</td>
<td>Osteoporosis and Other Bone/Cartilage</td>
</tr>
<tr>
<td>Osteoporosis and Other Bone/Cartilage</td>
<td></td>
<td>Chronic Obstructive Pulmonary Disease</td>
</tr>
</tbody>
</table>

Table 4.3 - Prevalence of Top 10 Conditions by Members’ Cost Group
Brigham Health Bridge Clinic

- Low barrier, rapid access clinic for patients with SUDs
- Harm reduction approach for patients in all stages of recovery
- Walk-ins accepted

Inpatients with SUDs-related diagnoses requiring ongoing treatment

Primary Care

• Addiction Pharmacotherapy
• Individual and group support services
• Co-treatment of complications with Specialty services (ID, Cards)
• Assistance with social services
• Connection to long-term care

Primary Care

Longer-term SUDs treatment

Community Resources

ED Patients presenting with SUDs not needing inpatient-level care
Referrals: Types of patients

- Patients identified with any Substance Use Disorders (SUDs) or receiving care for medical complications related to substance use
  - Alcohol/Benzodiazepine dependence/withdrawal
  - Infections related to intravenous drug use
  - Opioid overdose +/- naloxone reversal
  - Ongoing cocaine, heroin, fentanyl use
Brigham Health Bridge Clinic

Roles and Services:

• **Addiction Psychiatry and Medicine physicians**
  – Perform intake, prescribe medications, monitor comorbid medical and mental health complications

• **Recovery Coach**
  – Provide peer support services; connect pts with long-term SUDs programs in community
  – Co-leads group sessions

• **Care Transition Specialist**
  – Screen for social determinants of health and connect pts with community resources (e.g., housing, food, transportation)

Available Medications:

• Buprenorphine (OUD)
• Oral Naltrexone (OUD, AUD)
• Intramuscular Vivitrol (OUD, AUD)
Goal: 100% Attending EPs Waivered

Friday, February 9, 2018

#GetWaivered

With limited resources and access to treatments for addiction, emergency rooms across the country have become the first point of contact for many people with substance use disorders, but the lack of opportunity for follow-up leaves many emergency providers powerless when a patient is ready to begin their path to recovery. To better equip providers in the MGH Emergency Department (ED) with more substantial and evidence-based options for treating these patients, many at the MGH are changing where and when recovery begins.

The #GetWaivered program – introduced by Alister Martin, MD, a resident in Emergency Medicine, and Ali Raja, MD, executive vice chair of Emergency Medicine – encourages providers to participate in the training necessary to prescribe buprenorphine – a medication that curbs opioid cravings and reduces the effects of opioid withdrawal in the hopes of helping patients stay in treatment longer – usually only prescribed by addiction medicine specialists.
277 patients have been referred to the Bridge Clinic → 75% presented for at least 1 appointment

Demographics:
- Ages: 23-70
- Gender: 69% male, 31% female
- Insurance: 60% MassHealth, 17% Medicare, 23% Commercial

Social Determinants:
- 28% Homeless
- 23% have no phone
- 20% have no Identification Card

SUDs diagnoses:
- 67% have OUD diagnosis (95% on buprenorphine)
- 40% have AUD diagnosis (83% on naltrexone/Vivitrol)
- 32% have polysubstance (most often cocaine or benzos)
Brigham Health Bridge Clinic (April – January 2019)

✧ 277 patients have been referred to the Bridge Clinic → 75% presented for at least 1 appointment

✧ Of the 207 patients that have engaged with the Bridge Clinic at least once:
  – 85% remain in treatment—either at the Bridge Clinic or in longer-term care
  – ED visits decreased by 66% within the 3 months after referral**
  – Inpatient admissions decreased by 60% within the 3 months after referral**

**For patients with 3 months of follow-up after Bridge Clinic referral
Bridge Clinic Outpatient Parenteral Antibiotic Therapy (OPAT) Program
Safe housing
- Ideally with sober support at home
- No one at home is using intravenous drugs
- Engaged in treatment for substance use disorder
  - Suboxone or Methadone
  - Agrees to return to Bridge clinic twice/week while on IV antibiotics
  - Agrees to follow up in BWH ID clinic
- Not engaging in illicit substance use or violent behavior during latter part of hospitalization
- Multidisciplinary assessment confirms the patient is appropriate for discharge home
Bridge-OPAT patients (April – December 2018)

• 17 patients with OUD, history of IDU completed IV antibiotic course at home with close follow-up in the Bridge Clinic
  • 10 buprenorphine, 6 methadone, 1 N/A (cocaine use)

• All 17 have completed antibiotic course and PICC lines removed
  • Only 1 patient (on methadone) had readmission for a bloodstream infection, subsequently discharged on oral antibiotics
  • No other complications, relapses

• Collectively, for these 17 patients, avoided 531 inpatient/rehab days.
Assuring Addiction Treatment at a Safety Net Hospital

Lewis S. Nelson, MD
Professor of Emergency Medicine
Rutgers New Jersey Medical School
University Hospital of Newark
Newark, NJ
Buprenorphine Dosing Guideline for Acute Opioid Withdrawal

Confirm time since last opioid use (hospital)
- Short-acting (e.g., heroin/morphine MR) >12 hours
- Extended release formulations (e.g., OxyContin®, Oxycodone) >24 hours
- On methadone maintenance >72 hours (consider methadone instead of buprenorphine)

Evaluate Clinical Opiate Withdrawal Scale (COWS)

No buprenorphine indicated
Re-assess COWS in 1-2 hours

≥ 8

Give buprenorphine 4-8 mg SL*
4 mg – COWS 8-12
8 mg – COWS ≥ 13

≥ 8

< 8

Yes

No

Are you DATA-waivered?

Repeat or double buprenorphine dose
Max single dose = 8 mg
Max total dose = 16 mg

- Refer to outpatient buprenorphine clinic (warm handoff preferred)
- If possible, consult a DATA-waivered physician to write a buprenorphine/naloxone prescription
- Instruct to return to ED if withdrawal occurs before pt can get to the clinic (see 72 hr rule below)
- Offer naloxone rescue kit**

No

Re-assess after 1 hour
Is clinical withdrawal present?

- Refer to outpatient buprenorphine clinic (warm handoff preferred)
- Write a buprenorphine/naloxone prescription for 4-8 days until patient can follow-up at the clinic. Counsel the patient on appropriate dosing.
- Instruct patient to return to ED if withdrawal occurs before pt can fill the Rx or follow-up at the clinic (see 72 hr rule below)
- Offer naloxone rescue kit***
- If needed and time permits, begin the prior authorization process by calling the patient’s insurance company

Sample discharge prescription for a 3-day supply
Buprenorphine/naloxone 8 mg/2 mg SL tablet or film
Take 1 tablet/film twice daily
Dispense #6
No Refills

*Pretreatment patient that buprenorphine tablets take 5-10 minutes to dissolve and should remain under the tongue until it is completely dissolved

**Please refer to the “Naloxone Rescue Kit Protocol” available on MCT’s and ED Guideline folders (for desk top) and besides

***Pretreatment patient that buprenorphine tablets take 5-10 minutes to dissolve and should remain under the tongue until it is completely dissolved

ADJUNCTIVE THERAPY - Consider if withdrawal persists after maximum dose of buprenorphine given
General withdrawal symptoms
Clonidine 0.1 mg PO Q4H PRN (hold for SBP < 90 mmHg)
Nausea and vomiting
Ondansetron 4 mg IV Q8H PRN
Diarrhea
Loperamide 4 mg PO, then 2 mg PO Q2H PRN (max total dose = 8 mg)
Mialgias and arthralgias
Ibuprofen 600 mg PO Q6H PRN

Guidelines are intended to be flexible. They serve as reference points or recommendations, not rigid criteria. Guidelines should be followed in most cases, but there is an understanding that, depending on the patient, setting, circumstances or factors, guidelines can and should be tailored to fit individual needs.
The Landscape

✧ Clinic half-day per week
  – 40% of overall patients are uninsured
  – Majority of the others are Medicaid

✧ No peer navigators, recovery coaches, or consistent social work support
  – Control arm for a peer navigator study
  – Developed student navigator program

✧ Naloxone distribution program

✧ Most physicians not waivered
  – 6/35 with clear interest in addiction management

✧ Very collaborative relationship with addiction psychiatry
Suboxone (Buprenorphine) Clinic

Every Thursday, 12pm – 4pm

Behavioral Health Sciences Building (BHSB)
183 South Orange Ave, F-Level

Phone: 973-440-8179

We are located in the “BHSB” building as shown on the bottom of the map.
Tell the security guard you are going to F-level to see Dr. Zerbo.
Please call the phone number above if you have any questions.
Emergency Narcotic Addiction Treatment

The Drug Enforcement Administration (DEA) and Center for Substance Abuse Treatment (CSAT) have received numerous inquiries requesting clarification of the three-day (72 hour) exception to the separate registration requirement for maintenance or detoxification treatment. In addition, confusion continues to exist whether practitioners may prescribe Buprenex, a Schedule III Schedule V controlled substance for maintenance and detoxification treatment.

A practitioner who dispenses Schedule II narcotic drugs for maintenance and/or detoxification must obtain separate registration as a narcotic treatment program pursuant to the Narcotic Addict Treatment Act of 1974. This registration allows a practitioner to administer or dispense, but not prescribe, Schedule II narcotic drugs that are approved by the United States Food and Drug Administration (FDA) for the treatment of narcotic addiction. Methadone and levo-alpha-acetyl-methadol (LAAM) are the only drugs approved for use in maintenance and detoxification treatment. If a practitioner plans to use any other narcotic drug for addiction treatment, prior authorization must be obtained from FDA through an Investigational New Drug Application. Registration with DEA is contingent upon proper registration with the State Methadone Authority, and Health and Human Services.

An exception to the registration requirement, known as the "three day rule" (Title 21, Code of Federal Regulations, Part 1306.07(b)), allows a practitioner who is not separately registered as a narcotic treatment program, to administer (but not prescribe) narcotic drugs to a patient for the purpose of relieving acute withdrawal symptoms while arranging for the patient’s referral for treatment, under the following conditions:

1. Not more than one day’s medication may be administered or given to a patient at one time
2. This treatment may not be carried out for more than 72 hours and;
3. This 72-hour period cannot be renewed or extended

The intent of 21 CFR 1306.07(b) is to provide practitioner flexibility in emergency situations where he may be confronted with a patient undergoing withdrawal. In such emergencies, it is impractical to require practitioners to obtain a separate registration. The 72-hour exception offers an opioid dependent individual relief from experiencing acute withdrawal symptoms, while the physician arranges placement in a maintenance/detoxification treatment program. This provision was established to augment, not to circumvent the separate registration requirement.
Center of Excellence Grant
The Landscape

- Peer navigator program
- 5 weekday clinic availability
  - Incorporating our interested physicians
  - Insurance unimportant
- Funding for waiver training
- Very collaborative relationship with addiction psychiatry
Moderated Discussion

✧ What hurdles have you faced in the development and implantation process?
  – How have you addressed them

✧ For the larger EM community, especially outside of academic medical centers, what additional hurdles should be anticipated?

✧ How important is the DATA waiver for emergency physicians?